Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs

Artery. 1980;8(2):113-9.


In this study we examined the influence of different lipid lowering drugs (xantinolnicotinate (Xn), bezafibrate (Bf) and a combination of inositolnicotinate and clofibrate (In-Cl)) on the lipid and lipoprotein concentration in 61 hyperlipidemics of the types IIb, IV and V. Treatment with the 3 drugs showed a significant LDL-cholesterol decrease in type IIb and a LDL-cholesterol increase in the types IV and V. Concerning protective HDL lipoproteins an increase of HDL-cholesterol could be observed in all three types only by treatment with xantinolnicotinate and bezafibrate. Concomitantly in type V a type conversion to type IV could be observed under drug treatment regarding the chemical composition of the lipoprotein fractions VLDL, LDL and HDL.

MeSH terms

  • Anticholesteremic Agents / therapeutic use*
  • Bezafibrate
  • Cholesterol / blood*
  • Clofibrate / therapeutic use
  • Clofibric Acid / analogs & derivatives
  • Clofibric Acid / therapeutic use
  • Humans
  • Hyperlipoproteinemia Type II / blood
  • Hyperlipoproteinemia Type II / drug therapy*
  • Hyperlipoproteinemia Type IV / blood
  • Hyperlipoproteinemia Type IV / drug therapy*
  • Hyperlipoproteinemia Type V / blood
  • Hyperlipoproteinemia Type V / drug therapy*
  • Inositol / analogs & derivatives*
  • Inositol / therapeutic use
  • Lipoproteins / blood*
  • Nicotinic Acids / therapeutic use*
  • Xanthinol Niacinate / therapeutic use


  • Anticholesteremic Agents
  • Lipoproteins
  • Nicotinic Acids
  • Inositol
  • Clofibric Acid
  • Xanthinol Niacinate
  • Cholesterol
  • Inositol Niacinate
  • Clofibrate
  • Bezafibrate